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ABSTRACT 
Objective  
To determine whether patients with paroxysmal atrial fibrillation (AF) are less likely to be 
treated with anticoagulants than patients with persistent/permanent AF, and to investigate 
trends in treatment between 2000 and 2015. UK and European guidelines recommend that 
anticoagulants are offered to all AF patients at increased risk of stroke, irrespective of AF 
type. 
Methods 
16 sequential cross-sectional analyses from 2000 to 2015 were carried out with index dates 
on 1st May each year. The data source was primary care data from 648 practices across the 
UK contributing to The Health Improvement Network (THIN) database. All patients with a 
diagnosis of AF aged ≥ 35 years and registered for at least one year were included. The main 
outcome measure was prescription of anticoagulant medication. 
Results 
The proportion of AF patients with a diagnosis of paroxysmal AF increased from 7.4% (95% 
CI 7.0, 7.8) in 2000 to 14.0% (95% CI 13.7, 14.3) in 2015. Among patients with a CHADS2 
score ≥ 1, between 2000 and 2015 the proportion prescribed anticoagulants increased from 
18.8% (95% CI 16.4, 21.4) to 56.2% (95% CI 55.0, 57.3) and from 34.2% (95% CI 33.3, 
35.0) to 69.4% (95% CI 68.9, 69.8) in paroxysmal and other (persistent/permanent) AF 
patients respectively; RR for treatment of paroxysmal AF patients compared to other AF 
patients increased from 0.48 (95% CI 0.42, 0.55) to 0.76 (95% CI 0.74, 0.77). Adjusting for 
age, sex, Townsend score and presence or absence of contraindications had little effect on the 
results. 
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Conclusions 
In 2000, eligible paroxysmal AF patients were half as likely to be treated with anticoagulants 
as other AF patients; this has improved over time, but in 2015, eligible paroxysmal AF 
patients were still around 20% less likely to be prescribed anticoagulant medication.  
 
KEY MESSAGES 
What is already known about this subject? 
Patients with paroxysmal atrial fibrillation (AF) are at an elevated risk of stroke. Guidelines 
recommend anticoagulants for patients with paroxysmal AF.  
What does this study add? 
In 2000 patients with paroxysmal AF were half as likely to be prescribed anticoagulants as 
those with permanent AF. In 2015 patients with paroxysmal AF were 20% less likely to be 
prescribed anticoagulants as those with permanent AF. 
How might this impact on clinical practice? 
Clinicians should be aware that eligible patients with paroxysmal AF should be prescribed 
anticoagulants. 
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THE TREATMENT OF PAROXYSMAL ATRIAL FIBRILLATION IN UK 
PRIMARY CARE 
INTRODUCTION 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major global 
public health problem. It is associated with a five-fold increase in risk of stroke, increased 
incidence of congestive heart failure, and higher mortality.1 
Recurrent AF is either labelled ‘paroxysmal’ when it is self-terminating or ‘persistent’ when 
it lasts more than 7 days or is terminated earlier using either pharmacological means or direct 
current cardioversion; AF is defined as permanent when cardioversion fails to restore normal 
heart rhythm.2 Evidence varies regarding the similarity in stroke risk between paroxysmal, 
persistent and permanent AF patients: some studies have shown comparable stroke risk, 
while others suggest that risk may be lower in paroxysmal AF patients.3,4,5,6,7,8 Nevertheless, 
paroxysmal AF patients remain at an elevated risk of stroke relative to patients without AF. 
Within 1.5 years over a fifth of patients with paroxysmal AF progress to permanent AF.9,10  
Prophylactic treatment of AF with anticoagulants reduces risk of stroke by approximately two 
thirds.11,12,13,14,15 Current UK and European guidelines recommend that anticoagulants are 
offered to all AF patients with a CHA2DS2-VASc score ≥ 2, and are considered for men with 
a CHA2DS2-VASc score of 1, regardless of whether the pattern of AF is paroxysmal, 
persistent or permanent, or the duration of AF.1,16,17,18 
Recent data from two international studies, the GARFIELD Registry and the GLORIA-AF 
Registry, indicate that anticoagulant therapy is not consistently prescribed across AF 
categories, with lower rates of use in paroxysmal AF patients than in those with persistent or 
permanent AF.19,20,21   
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The aim of this analysis was to determine whether patients with paroxysmal AF are less 
likely to be treated with anticoagulants than patients with persistent or permanent AF in the 
UK, and to investigate trends in treatment between 2000 and 2015. To date, this question has 
not been addressed in a UK primary care setting. 
METHODS 
Data source 
Analysis was performed using data from The Health Improvement Network (THIN), an 
anonymised database of electronic medical records from UK general practices using Vision 
software. The version of the THIN database used in this study (THIN1505) included primary 
care data for approximately 14.0 million patients at 648 practices across the UK. General 
practices were eligible for inclusion in the study from the latest of: the practice acceptable 
mortality recording (AMR) date,22 the Vision installation date, and the study start date (one 
year prior to the first index date). 
Study design 
Sixteen sequential cross-sectional analyses were carried out with index dates on 1st May each 
year from 2000 to 2015. All analyses were conducted using StataIC 13. Data was not used 
prior to 2000 as there were fewer practices and patients contributing data, and data accuracy 
is better in more recent years. 
The study population included all patients with a diagnosis of atrial fibrillation aged 35 years 
and over on the index date who were registered at least one year prior to the index date. The 
exposure was a diagnosis of paroxysmal AF, with all other types of AF (persistent or 
permanent AF, hereafter referred to as ‘other AF’) as the comparator group. Outcome was 
treatment with anticoagulants. 
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Analysis 
The proportions of patients with paroxysmal AF and other AF prescribed anticoagulants on 
each index date were calculated, with 95% confidence intervals (CI); p-values for trends in 
treatment between 2000 and 2015 were calculated using chi-squared tests. Patients were 
stratified according to eligibility for anticoagulant treatment: in primary analysis, this was 
defined according to CHADS2 score (≥ 1), since CHADS2 score has been in use for a longer 
period of time than CHA2DS2-VASc score;23,24 in sensitivity analysis, eligibility was defined 
according to CHA2DS2-VASc score (≥ 1). Crude and adjusted risk ratios (RR) were 
calculated on each index date. RRs were calculated using Cox regression, setting follow-up 
time to 1 for all patients, using the Breslow method to break ties, and using the robust 
variance estimator;25 RRs were adjusted for age and sex only, and for age, sex, Townsend 
score, CHADS2 score, and presence of any contraindication. 
Definitions of variables 
AF was defined as a clinical code for atrial fibrillation or atrial flutter recorded ever prior to 
the index date, excluding patients with a clinical code indicating AF resolved recorded on or 
after the last recorded AF clinical code and prior to the index date. Patients were categorised 
as having paroxysmal AF if the last AF clinical code prior to the index date indicated 
paroxysmal atrial fibrillation or paroxysmal atrial flutter; otherwise patients were categorised 
as having other (persistent or permanent) AF. Current anticoagulant treatment was defined as 
a record of a prescription for any anticoagulant drug (including warfarin, parenteral 
anticoagulants, other vitamin K antagonists and new oral anticoagulants) within 90 days prior 
to the index date or a clinical code indicating provision of anticoagulant therapy within 365 
days prior to the index date. 
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CHADS2 scores were calculated by adding one point for a history of congestive heart failure, 
hypertension, age ≥ 75 and diabetes, and two points for a history of stroke or transient 
ischaemic attack (TIA). CHA2DS2-VASc scores were calculated by adding one point for a 
history of congestive heart failure, hypertension, diabetes, vascular disease, age 65-74 years 
and female sex (if another risk factor was present, otherwise 0), and two points for age ≥ 75 
and history of stroke, TIA or thromboembolism. History of congestive heart failure, stroke, 
TIA, thromboembolism, vascular disease and diabetes were defined by a relevant clinical 
code recorded ever prior to the index date, excluding patients with a clinical code indicating 
diabetes resolved recorded after the last recorded diabetes code and prior to the index date; 
hypertension was defined as a current (previous 90 days) prescription of antihypertensive 
drugs or the mean of the three most recent systolic blood pressures in the last 3 years ≥160 
mm Hg. 
Contraindications to anticoagulants were defined as a clinical code within the 2 years prior to 
the index date of peptic ulcer, intracranial, intraocular or retroperitoneal bleeding, bleeding 
disorders, haemorrhagic stroke, oesophageal varices, aneurysm, or proliferative retinopathy; a 
clinical code recording allergy or adverse reactions to anticoagulants ever prior to the index 
date; a clinical code indicating pregnancy in the 9 months prior to the index date; or severe 
hypertension with a mean (of the 3 most recent measures in the last 3 years prior to the index 
date) systolic blood pressure >200 mm Hg or diastolic blood pressure >120 mm Hg. 
RESULTS 
A total of 179,343 of the 4,419,659 patients eligible for inclusion in the study between 2000 
and 2015 had AF. As an individual could contribute to the analysis in more than one year, the 
analyses consisted of a total of 848,852 AF patient records. The proportion of AF patients 
with a diagnosis of paroxysmal AF increased from 7.4% (95% CI 7.0, 7.8) in 2000 to 14.0% 
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(95% CI 13.7, 14.3) in 2015, an increase in prevalence from 0.14% (95% CI 0.13, 0.15) to 
0.43% (95% CI 0.42, 0.44). Baseline characteristics of paroxysmal and other 
(persistent/permanent) AF patients are shown in Table 1. Across all years, in paroxysmal 
compared to other AF patients the mean age was 4.5 years (95% CI 4.4, 4.6) lower; 6.4% 
(95% CI 6.1, 6.7) fewer were males; mean CHADS2 score was 0.43 (95% CI 0.42, 0.44) 
points lower; 1.6% (95% CI 1.4, 1.8) fewer were in the most deprived Townsend quintile; 
and 0.5% (95% CI 0.4, 0.7) fewer had one or more contraindications to anticoagulants. 
Over the 15 year period studied, the proportion of paroxysmal AF patients prescribed 
anticoagulants increased from 16.0% (95% CI 14.0, 18.2) to 50.7% (95% CI 49.6, 51.8), 
while the proportion of other AF patients prescribed anticoagulants increased from 33.5% 
(95% CI 32.7, 34.3) to 67.1% (95% CI 66.6, 67.5). Among eligible patients only, defined as 
those with a CHADS2 score of 1 or more, the proportion of paroxysmal AF patients 
prescribed anticoagulants increased from 18.8% (95% CI 16.4, 21.4) to 56.2% (95% CI 55.0, 
57.3), and the proportion of other AF patients increased from 34.2% (95% CI 33.3, 35.0) to 
69.4% (95% CI 68.9, 69.8) (Figure 1). 
In 2000, paroxysmal AF patients were half as likely to receive anticoagulant treatment as 
other AF patients, risk ratio (RR) 0.48 (95% CI 0.42, 0.55); this disparity has declined, 
particularly since 2011/12, but in 2015, paroxysmal AF patients are still less likely to be 
prescribed anticoagulants, RR 0.76 (95% CI 0.74, 0.77) (Table 2). Adjusting for age, sex, 
Townsend score, CHADS2 score and presence or absence of contraindications made only a 
small difference to the results: fully adjusted RR increased from 0.41 (95% CI 0.36, 0.48) in 
2000 to 0.77 (95% CI 0.75, 0.79) in 2015. 
Among only those AF patients eligible for anticoagulant treatment, RR increased from 0.55 
(95% CI 0.48, 0.63) to 0.81 (95% CI 0.79, 0.83) between 2000 and 2015. Adjusting for age, 
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sex, Townsend score and presence or absence of contraindications had little effect on the 
results in recent years, but caused an increase in effect size in earlier years: adjusted RR 
increased from 0.46 (95% CI 0.40, 0.53) in 2000 to 0.80 (95% CI 0.79, 0.82) in 2015 (Table 
2); the slightly increased effect of adjustment in earlier years is likely to be due the greater 
difference in mean age between paroxysmal and other AF patients, particularly between 2000 
and 2006. In sensitivity analysis, eligibility for anticoagulant treatment was defined according 
to CHA2DS2-VASc score (1 or more); this made only a marginal difference to the observed 
RRs (Supplementary Table 1).  
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Table 1: Baseline characteristic of AF patients with paroxysmal or other AF, 2000-2015 
Year AF type n (%) Age Sex (male) CHADS2 score 
Most 
deprived 
quintile 
One or 
more 
contra-
indication 0 1 2+ 
    
  Mean (SD) n (%) n (%) n (%) n (%) n (%) n (%) 
2000 Paroxysmal  1169 (7.4) 69.4 (12.5) 589 (50.4) 248 (21.2) 448 (38.3) 473 (40.5) 145 (13.1) 62 (5.3) 
Other  14627 (92.6) 75.5 (10.7) 7567 (51.7) 1613 (11.0) 3982 (27.2) 9032 (61.8) 1906 (14.0) 771 (5.3) 
2001 Paroxysmal  2111 (8.6) 70.5 (12.4) 1027 (48.7) 422 (20.0) 759 (36.0) 930 (44.1) 226 (11.2) 117 (5.5) 
Other  22426 (91.4) 75.6 (10.8) 11740 (52.4) 2296 (10.2) 6018 (26.8) 14112 (62.9) 2731 (12.9) 1298 (5.8) 
2002 Paroxysmal  2980 (9.4) 70.4 (12.3) 1467 (49.2) 574 (19.3) 1051 (35.3) 1355 (45.5) 316 (11.1) 183 (6.1) 
Other  28713 (90.6) 75.8 (10.7) 15101 (52.6) 2707 (9.4) 7439 (25.9) 18567 (64.7) 3492 (12.8) 1843 (6.4) 
2003 Paroxysmal  4126 (10.1) 70.7 (12.2) 2023 (49.0) 762 (18.5) 1409 (34.2) 1955 (47.4) 441 (11.2) 270 (6.5) 
Other  36762 (89.9) 75.8 (10.8) 19510 (53.1) 3235 (8.8) 9469 (25.8) 24058 (65.4) 4355 (12.5) 2326 (6.3) 
2004 Paroxysmal  4827 (10.6) 70.9 (12.2) 2333 (48.3) 789 (16.4) 1645 (34.1) 2393 (49.6) 519 (11.1) 313 (6.5) 
Other  40502 (89.4) 76.0 (10.8) 21533 (53.2) 3298 (8.1) 10162 (25.1) 27042 (66.8) 4716 (12.1) 2658 (6.6) 
2005 Paroxysmal  5588 (10.9) 71.1 (12.3) 2705 (48.4) 905 (16.2) 1873 (33.5) 2810 (50.3) 568 (10.4) 336 (6.0) 
Other  45584 (89.1) 76.1 (10.8) 24411 (53.6) 3460 (7.6) 11478 (25.2) 30646 (67.2) 5209 (11.8) 2944 (6.5) 
2006 Paroxysmal  6476 (11.6) 71.4 (12.2) 3127 (48.3) 1022 (15.8) 2162 (33.4) 3292 (50.8) 661 (10.5) 350 (5.4) 
Other  49463 (88.4) 76.2 (10.9) 26666 (53.9) 3586 (7.3) 12301 (24.9) 33576 (67.9) 5645 (11.8) 3152 (6.4) 
2007 Paroxysmal  6781 (11.6) 72.0 (12.1) 3269 (48.2) 923 (13.6) 2242 (33.1) 3616 (53.3) 658 (10.0) 371 (5.5) 
Other  51714 (88.4) 76.6 (10.7) 28036 (54.2) 3224 (6.2) 12689 (24.5) 35801 (69.2) 5739 (11.4) 3116 (6.0) 
2008 Paroxysmal  7460 (12.1) 72.3 (12.0) 3556 (47.7) 960 (12.9) 2453 (32.9) 4047 (54.3) 715 (9.8) 372 (5.0) 
Other  54066 (87.9) 76.8 (10.7) 29567 (54.7) 3099 (5.7) 12938 (23.9) 38029 (70.3) 6048 (11.5) 3238 (6.0) 
2009 Paroxysmal  8299 (12.7) 72.4 (11.9) 3981 (48.0) 1029 (12.4) 2733 (32.9) 4537 (54.7) 794 (9.8) 437 (5.3) 
Other  57253 (87.3) 76.8 (10.6) 31659 (55.3) 3019 (5.3) 13554 (23.7) 40680 (71.1) 6288 (11.2) 3532 (6.2) 
2010 Paroxysmal  8620 (13.0) 72.4 (12.1) 4175 (48.4) 1065 (12.4) 2818 (32.7) 4737 (55.0) 830 (9.9) 463 (5.4) 
Other  57825 (87.0) 76.9 (10.7) 32263 (55.8) 2899 (5.0) 13567 (23.5) 41359 (71.5) 6316 (11.2) 3561 (6.2) 
2011 Paroxysmal  9182 (13.5) 72.6 (12.0) 4413 (48.1) 1090 (11.9) 2982 (32.5) 5110 (55.7) 863 (9.6) 516 (5.6) 
Other  59011 (86.5) 77.0 (10.7) 33171 (56.2) 2891 (4.9) 13689 (23.2) 42431 (71.9) 6356 (11.0) 3587 (6.1) 
2012 Paroxysmal  9641 (13.8) 72.7 (12.0) 4650 (48.2) 1138 (11.8) 3065 (31.8) 5438 (56.4) 875 (9.3) 514 (5.3) 
Other  60012 (86.2) 77.0 (10.7) 33900 (56.5) 2899 (4.8) 13834 (23.1) 43279 (72.1) 6508 (11.1) 3734 (6.2) 
2013 Paroxysmal  9638 (13.9) 72.7 (12.0) 4754 (49.3) 1156 (12.0) 3015 (31.3) 5467 (56.7) 890 (9.5) 551 (5.7) 
Other  59595 (86.1) 76.9 (10.8) 33956 (57.0) 2984 (5.0) 13677 (23.0) 42934 (72.0) 6618 (11.4) 3697 (6.2) 
2014 Paroxysmal  9368 (14.0) 72.7 (12.1) 4674 (49.9) 1136 (12.1) 2919 (31.2) 5313 (56.7) 860 (9.4) 568 (6.1) 
Other  57580 (86.0) 76.9 (10.8) 32939 (57.2) 2913 (5.1) 13028 (22.6) 41639 (72.3) 6206 (11.0) 3525 (6.1) 
2015 Paroxysmal  8036 (14.0) 72.7 (12.2) 4082 (50.8) 1006 (12.5) 2458 (30.6) 4572 (56.9) 753 (9.6) 467 (5.8) 
Other  49417 (86.0) 76.9 (10.9) 28534 (57.7) 2544 (5.2) 11172 (22.6) 35701 (72.2) 5428 (11.3) 2886 (5.8) 
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Figure 1. Proportion of paroxysmal and other AF patients prescribed anticoagulant 
treatment by CHADS2 score, 2000-2015 
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Table 2: Risk ratios for anticoagulant treatment of paroxysmal AF patients relative to other AF patients, 2000-2015 
Year 
All Eligible CHADS2 ≥ 1 
Ineligible 
CHADS2 = 0 
Unadjusted Adjusted for age 
and sex Fully adjusted
†
 Unadjusted Fully adjusted†† Unadjusted 
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
2000 0.48 (0.42, 0.55) 0.43 (0.37, 0.49) 0.41 (0.36, 0.48) 0.55 (0.48, 0.63) 0.46 (0.40, 0.53) 0.20 (0.12, 0.34) 
2001 0.50 (0.46, 0.55) 0.46 (0.42, 0.51) 0.46 (0.42, 0.51) 0.58 (0.53, 0.64) 0.52 (0.48, 0.58) 0.17 (0.11, 0.26) 
2002 0.45 (0.42, 0.49) 0.42 (0.39, 0.46) 0.42 (0.38, 0.45) 0.51 (0.47, 0.55) 0.47 (0.43, 0.51) 0.19 (0.13, 0.26) 
2003 0.48 (0.45, 0.51) 0.46 (0.43, 0.49) 0.46 (0.43, 0.49) 0.53 (0.50, 0.57) 0.50 (0.47, 0.53) 0.27 (0.21, 0.35) 
2004 0.51 (0.49, 0.54) 0.49 (0.46, 0.52) 0.49 (0.46, 0.52) 0.56 (0.53, 0.59) 0.52 (0.49, 0.55) 0.29 (0.23, 0.36) 
2005 0.53 (0.51, 0.56) 0.51 (0.49, 0.54) 0.51 (0.48, 0.53) 0.58 (0.55, 0.61) 0.54 (0.51, 0.57) 0.31 (0.25, 0.39) 
2006 0.53 (0.50, 0.55) 0.51 (0.49, 0.53) 0.51 (0.48, 0.53) 0.57 (0.55, 0.60) 0.54 (0.51, 0.56) 0.32 (0.26, 0.39) 
2007 0.54 (0.52, 0.57) 0.52 (0.50, 0.55) 0.52 (0.50, 0.54) 0.58 (0.56, 0.61) 0.55 (0.53, 0.58) 0.30 (0.24, 0.36) 
2008 0.54 (0.52, 0.56) 0.52 (0.50, 0.54) 0.52 (0.50, 0.54) 0.58 (0.56, 0.60) 0.55 (0.53, 0.57) 0.30 (0.25, 0.36) 
2009 0.56 (0.54, 0.58) 0.55 (0.53, 0.57) 0.55 (0.53, 0.56) 0.60 (0.58, 0.62) 0.58 (0.56, 0.60) 0.28 (0.23, 0.34) 
2010 0.58 (0.56, 0.60) 0.57 (0.55, 0.59) 0.57 (0.55, 0.59) 0.62 (0.60, 0.64) 0.60 (0.58, 0.62) 0.34 (0.28, 0.41) 
2011 0.60 (0.58, 0.62) 0.60 (0.58, 0.62) 0.60 (0.58, 0.62) 0.64 (0.62, 0.66) 0.63 (0.61, 0.65) 0.37 (0.31, 0.44) 
2012 0.63 (0.61, 0.64) 0.63 (0.61, 0.65) 0.63 (0.61, 0.64) 0.67 (0.65, 0.69) 0.65 (0.64, 0.67) 0.40 (0.33, 0.47) 
2013 0.67 (0.66, 0.69) 0.68 (0.66, 0.70) 0.68 (0.66, 0.70) 0.72 (0.70, 0.74) 0.71 (0.69, 0.73) 0.41 (0.34, 0.49) 
2014 0.71 (0.69, 0.73) 0.72 (0.71, 0.74) 0.72 (0.70, 0.74) 0.76 (0.74, 0.77) 0.75 (0.73, 0.77) 0.47 (0.40, 0.57) 
2015 0.76 (0.74, 0.77) 0.77 (0.76, 0.79) 0.77 (0.75, 0.79) 0.81 (0.79, 0.83) 0.80 (0.79, 0.82) 0.50 (0.42, 0.60) 
All p values < 0.001. †Adjusted for age, sex, Townsend score, CHADS2 score and presence or absence of contraindications 
(binary). ††Adjusted for age, sex, Townsend score and presence or absence of contraindications. 
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DISCUSSION 
Paroxysmal AF is becoming more commonly recorded as a diagnosis in UK primary care. 
Patients with paroxysmal AF are less likely to be treated with anticoagulants than patients 
with other types of AF: in 2000, paroxysmal AF patients who were eligible for treatment 
were almost half as likely to receive anticoagulants as other AF patients, and while this has 
been steadily improving over the last 15 years, paroxysmal AF patients continue to be around 
20% less likely to receive anticoagulants than other AF patients. This holds true after 
adjusting the data for age, sex and other potential confounders. The absolute anticoagulant 
treatment gap for paroxysmal AF remained relatively constant between 2002 and 2012, at 
around 20%; in recent years, this gap has narrowed, but remains around 13%.  
These results are consistent with findings from studies carried out in the USA among hospital 
outpatients with AF, in which paroxysmal AF patients were found to be around 20% less 
likely to receive oral anticoagulants than patients with persistent/permanent AF after 
adjusting for potential confounders.26,27 Similar results were also found in a study of AF 
patients admitted to hospital in Greece,28 and in the Euro Heart Survey on Atrial Fibrillation, 
an observational study of AF patients attending hospital in the ESC member countries 
(including the UK).29 No comparable studies using primary care data in the UK are known to 
the authors. 
ESC guideline-adherent antithrombotic management is associated with significantly better 
outcomes, including those related to mortality, thromboembolism, stroke and transient 
ischaemic attack.30 Current treatment practice does not appear to closely follow published 
treatment guidelines,31 which most likely results in elevated levels of preventable ischaemic 
stroke among patients with paroxysmal AF, even more so than in the wider atrial fibrillation 
population, leading to greater morbidity, mortality and overall cost to health care systems.32,33   
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Further research is needed to establish whether the difference in treatment between 
paroxysmal and other AF patients is the result of lower levels of treatment initiation by 
clinicians or whether paroxysmal AF patients are more likely to stop their treatment, and to 
explore reasons why this is the case.20 This will facilitate the development of methods to 
improve guideline adherence and/or uptake of anticoagulant prophylaxis, leading to improved 
outcomes for patients with paroxysmal AF.7 
Strengths and limitations 
This study utilises a large dataset which is representative of the AF population in UK primary 
care, and includes recent data up to 2015. The dataset comprises routinely collected data used 
by GPs to make clinical decisions. 
It is possible that AF type could be misclassified, as some cases of paroxysmal AF may be 
recorded under a non-specific AF clinical code; however, this is more likely to dilute rather 
than inflate observed effect sizes. Treatment may be underreported if patients are prescribed 
anticoagulants by their hospital; however, most anticoagulants are prescribed in primary care, 
and most secondary care prescriptions should be captured by anticoagulant/INR monitoring 
clinical codes, so underreporting is likely to be minimal. 
CONCLUSION 
Patients with paroxysmal AF are less likely to be treated with anticoagulants than patients 
with persistent or permanent AF. This difference is not explained by differences in patient 
demographics, stroke risk, or contraindications. The question remains as to whether the 
difference in treatment between paroxysmal and other AF patients is the result of lower levels 
of treatment initiation by clinicians or whether paroxysmal AF patients are more likely to 
stop their treatment, and to explore the reasons why.  
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Supplementary Table 1: Risk ratios for treatment of paroxysmal AF patients relative to 
other AF patients using CHA2DS2-VASc score to define eligibility, 2000-2015 
Year 
Eligible 
CHA2DS2-VASc ≥ 1 
Ineligible CHA2DS2-
VASc = 0 
Unadjusted Fully adjusted† Unadjusted 
RR (95% CI) RR (95% CI) RR (95% CI) 
2000 0.52 (0.46, 0.60) 0.44 (0.38, 0.51) 0.17 (0.08, 0.38) 
2001 0.55 (0.50, 0.60) 0.50 (0.45, 0.55) 0.16 (0.09, 0.30) 
2002 0.50 (0.46, 0.54) 0.45 (0.42, 0.49) 0.12 (0.06, 0.22) 
2003 0.52 (0.49, 0.55) 0.49 (0.45, 0.52) 0.27 (0.19, 0.40) 
2004 0.55 (0.52, 0.58) 0.52 (0.49, 0.54) 0.19 (0.12, 0.29) 
2005 0.57 (0.54, 0.59) 0.53 (0.51, 0.56) 0.25 (0.18, 0.37) 
2006 0.56 (0.53, 0.58) 0.53 (0.51, 0.55) 0.30 (0.22, 0.41) 
2007 0.58 (0.55, 0.60) 0.55 (0.52, 0.57) 0.22 (0.15, 0.31) 
2008 0.57 (0.55, 0.59) 0.54 (0.52, 0.56) 0.26 (0.19, 0.37) 
2009 0.59 (0.57, 0.61) 0.57 (0.55, 0.59) 0.23 (0.16, 0.33) 
2010 0.61 (0.59, 0.63) 0.59 (0.57, 0.61) 0.35 (0.26, 0.48) 
2011 0.63 (0.61, 0.65) 0.62 (0.60, 0.64) 0.34 (0.25, 0.47) 
2012 0.66 (0.64, 0.67) 0.64 (0.63, 0.66) 0.38 (0.27, 0.52) 
2013 0.71 (0.69, 0.72) 0.70 (0.68, 0.71) 0.41 (0.30, 0.57) 
2014 0.74 (0.73, 0.76) 0.74 (0.72, 0.76) 0.41 (0.29, 0.59) 
2015 0.80 (0.78, 0.81) 0.79 (0.78, 0.81) 0.37 (0.24, 0.56) 
 
All p values < 0.001. †Adjusted for age, sex, Townsend score and presence or absence of contraindications 
(binary). 
 
